Hoare et al describe a drug-repurposing approach and report that carvedilol, a β-arrestin-biased β-blocker, exhibits synergistic anti-ovarian cancer effects with oncolytic adenovirus. The study reveals that carvedilol augments the activity of oncolytic adenoviruses via β-arrestins to re-wire cytokine networks and innate immunity, resulting in increased oncolytic activity.
- Joseph I. Hoare
- Bleona Osmani
- Michelle Lockley
